

# Contents

Contributors ix

Symbols and abbreviations xi

---

## SECTION 1

### History, diagnosis, and epidemiology

1. **The history of rheumatoid arthritis** 3  
*David L. Scott*
2. **Diagnosis** 13  
*Daniel Aletaha and Helga Radner*
3. **The descriptive epidemiology of rheumatoid arthritis** 23  
*James Gwinnutt and Deborah Symmons*
4. **Modifiable and other risk factors for rheumatoid arthritis: A basis for prevention and better therapy** 33  
*Lars Klareskog and Lars Alfredsson*

---

## SECTION 2

### Pathogenesis

5. **Genetics and epigenetics of rheumatoid arthritis** 45  
*Anne Barton*
6. **Dysregulation of synovial fibroblasts in rheumatoid arthritis** 55  
*Thomas Crowley, Jason D. Turner, Andrew Filer, Andy Clarke, and Chris Buckley*
7. **Autoantibodies in rheumatoid arthritis** 65  
*Tom W.J. Huizinga*
8. **Dendritic cells and T cells in rheumatoid arthritis** 73  
*Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas*

9. **Mechanisms of bone and cartilage destruction** 85  
*Ulrike Harre and Georg Schett*

10. **Cytokines and other mediators** 95  
*Marina Frleta-Gilchrist and Iain B. McInnes*

---

## SECTION 3

### Clinical presentation

11. **Clinical features of rheumatoid arthritis** 109  
*Annette van der Helm-van Mil*
12. **Pre-rheumatoid arthritis** 121  
*Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan van Schaardenburg*
13. **Non-articular manifestations of rheumatoid arthritis** 133  
*Katherine Macdonald, Jennifer Hannah, and James Galloway*
14. **Comorbidity in rheumatoid arthritis** 145  
*Kimme Hyrich and Sarah Skeoch*

---

## SECTION 4

### Disease assessment

15. **Disease activity assessment in rheumatoid arthritis** 161  
*Josef Smolen*
16. **Synovial biopsies** 169  
*Douglas J. Veale and Ursula Fearon*
17. **Radiography in rheumatoid arthritis** 177  
*Charles Peterfy, Philip G. Conaghan, and Mikkel Østergaard*
18. **Ultrasound in rheumatoid arthritis** 195  
*Andrew Filer, Maria Antonietta D'Agostino, and Ilfita Sahbudin*
19. **Magnetic resonance imaging in rheumatoid arthritis** 207  
*Mikkel Østergaard, Philip G. Conaghan, and Charles Peterfy*

---

## SECTION 5

### Impact on life

20. **Patient physical function in rheumatoid arthritis** 221  
*Kathryn A. Gibson and Theodore Pincus*
21. **Fatigue** 251  
*Emma Dures and Neil Basu*
22. **Health economics of rheumatoid arthritis** 259  
*David L. Scott and Allan Wailoo*
23. **Rheumatoid arthritis and work** 271  
*Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James Galloway*

---

## SECTION 6

### Non-drug treatments

24. **Physical activity and exercise** 285  
*Lindsay M. Bearne and Christina H. Opava*
25. **Foot health** 297  
*Heidi J. Siddle and Anthony C. Redmond*
26. **Occupational therapy** 311  
*Alison Hammond, Joanne Adams, and Yeliz Prior*
27. **Self-management: A patient's perspective** 321  
*Marieke M.J.H. Voshaar*

---

## SECTION 7

### Drug treatments

28. **Analgesics, opioids, and NSAIDs** 331  
*Mark D. Russell and Nidhi Sofat*
29. **Glucocorticoids** 339  
*Johannes W.G. Jacobs, Marlies C. van der Goes, Johannes W.J. Bijlsma, and José A.P. da Silva*
30. **Conventional disease-modifying drugs** 355  
*David L. Scott*
31. **Tumour necrosis factor inhibitors** 371  
*Peter C. Taylor and Nehal Narayan*
32. **Interleukin-6 inhibitors** 389  
*Neelam Hassan and Ernest Choy*

33. **B-cell therapies** 399  
*Md Yuzaiful Md Yusof, Edward M. Vital, and Maya H. Buch*
34. **Biosimilars** 411  
*Vibeke Strand, Jeffrey Kaine, and John Isaacs*
35. **Immunogenicity in response to biologic agents** 425  
*Meghna Jani, John Isaacs, and Vibeke Strand*
36. **The use of JAK inhibitors in the treatment of rheumatoid arthritis** 443  
*Katie Bechman, James Galloway, and Peter C. Taylor*
37. **Combination therapy in rheumatoid arthritis** 457  
*Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler*
38. **Translation of new therapies: From bench to bedside** 463  
*Jeremy Sokolove*
39. **Adverse events in clinical studies in rheumatoid arthritis** 471  
*Mark Yates and James Galloway*

---

## SECTION 8

### Management and outcomes

40. **Prevention of rheumatoid arthritis** 487  
*Tom W.J. Huizinga, Annette van der Helm-van Mil, and Andrew Cope*
41. **Treatment targets and remission** 495  
*Kenneth F. Baker and Arthur G. Pratt*
42. **Clinical outcomes** 507  
*David L. Scott*
43. **Clinical recommendations** 519  
*Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K. Kvien*
44. **European biologics registers** 535  
*Angela Zink and Anja Strangfeld*
45. **Voluntary patient registries** 545  
*Jeff Greenberg and Sheetal Patel*

*Index* 551